Technology for Engineering Antibodies with Infinite Affinity for their Antigen

Tech ID: 11255 / UC Case 2000-123-0

Full Description

Technology for engineering antibodies to bind irreversibly to their receptor has been developed by UC Davis researchers. This technology, enabling the formation of permanent antibody-antigen complexes has a number of potential applications in chemistry and biology, including:

  • targeted medical imaging
  • targeted medical therapies (e.g., cancer therapeutics)
  • synthetic tag to replace avidin-biotin
    • no competition from endogenous ligands
    • no dissociation after capture
    • humanized format

Furthermore, UC Davis researchers have constructed a bispecific fusion protein that has tumor targeting properties and irreversibly captures a metal chelate. This combines irreversible metal chelate binding with tumor targeting activity for the first time in a highly homogenous genetic construction that can be expressed at high yields. In addition, this allows the substitution of other targeting sequences allowing for a wide range of cellular targets. The irreversible nature of the chelate binding has not been previously achieved in a single expressed protein fused to a tumor targeting functional segment.


  • Chemistry
  • Biology
  • Pretargeted radioimmunotherapy (RAIT) applications


  • Alternative to combinatorial selection, directed evolution, or other methods for improving the affinity of antibodies to ligands

Related Materials

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 7,820,787 10/26/2010 2001-433
United States Of America Issued Patent 7,118,745 10/10/2006 2000-123


Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information


antibodies, irreversible binding, antibody-antigen complexes, permanent, bispecific fusion, chelate binding

Categorized As